MoonLake Immunotherapeutics, (MLTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MLTX Stock Price Chart Interactive Chart >
MLTX Price/Volume Stats
| Current price | $21.98 | 52-week high | $25.32 |
| Prev. close | $21.85 | 52-week low | $4.25 |
| Day low | $21.38 | Volume | 60,936 |
| Day high | $22.39 | Avg. volume | 187,227 |
| 50-day MA | $18.01 | Dividend yield | N/A |
| 200-day MA | $10.55 | Market Cap | 1.16B |
MoonLake Immunotherapeutics, (MLTX) Company Bio
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest MLTX News From Around the Web
Below are the latest news stories about MOONLAKE IMMUNOTHERAPEUTICS that investors may wish to consider to help them evaluate MLTX as an investment opportunity.
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst PathCantor Fitzgerald has initiated coverage on MoonLake Immunotherapeutics AG (NASDAQ: MLTX) with an Overweight rating and a price target of $23. MoonLake's lead program Sonelokimab or SLK (IL-17A & IL-17F nanobody), is currently in Phase 2 trials in Hidradenitis Suppurativa (HS-severe skin disease) and Psoriatic Arthritis (PsA). A more than $5 billion opportunity for SLK in HS is the primary driver of the analyst's bullish view. Also See: HC Wainwright Starts Coverage On This 'Best-In-Class Agent |
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativaMoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an |
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritisMoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis clinical development, assessing high threshold outcomes across joint and skin domains of this multi-faceted diseaseGlobal study to assess efficacy and safety of sonelokimab compared to placebo, with adalimumab as an active reference armSonelokimab is an investigational Nanobody® designed to treat inflammato |
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business UpdateMoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa (HS) has continued to meet recruitment targets with an expected primary endpoint readout in mid-2023Global Psoriatic Arthritis (PsA) trial received FDA clearance and US central IRB approvalQuarter-end position of $83.5 million in cash, cash equivalents and short-term marketable debt securities, providing cash runway into 2H2024 and a |
Analysts Are Bullish on Top Healthcare Stocks: First Wave Bio (FWBI), Atara Biotherapeutics (ATRA)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on First Wave Bio (FWBI – Research Report), Atara Biotherapeutics (ATRA – Research Report) and MoonLake Immunotherapeutics (MLTX – Research Report) with bullish sentiments. First Wave Bio (FWBI) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on First Wave Bio, with a price target of $8.00. The company's shares closed last Friday at $1.13, close to its 52-week low of $1.06. According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -30.8% and a 21.5% success rate. |
MLTX Price Returns
| 1-mo | 9.90% |
| 3-mo | 109.33% |
| 6-mo | 183.25% |
| 1-year | 98.02% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 109.33% |
| 2022 | 6.17% |
| 2021 | -13.02% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...